M42 Announces Strategic Investment and Partnership with Leading Biotech Juvenescence
M42 announces a strategic investment and partnership with Juvenescence, a leading biotech company focused on extending human healthspan. This collaboration aims to develop cutting-edge therapies and advance research in longevity and age-related diseases.
Chrysea Unveils Groundbreaking Findings on Spermidine Dietary Intake and Cardiovascular Health at American Physiological Society (APS) Summit.
Extensive scientific research has long established the critical role of spermidine in activating autophagy, a vital cellular process that removes damaged cells and declines with age.
Data and Safety Monitoring Board Approves LyGenesis’s Phase 2a Clinical Trial to Continue and Dose Escalate in Novel Trial of Organ Regeneration
The next four patients will receive a higher dose of LyGenesis's cell therapy to grow functioning liver tissue in patients with end stage liver disease.
Morphoceuticals
Listen in to Prof Michael Levin & Prof David Kaplan discussing the Morphoceuticals vision and groundbreaking approach of mapping & manipulating the bioelectrome to induce regeneration.
Juvenescence Appoints Dr Richard Marshall CBE as CEO
Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan.
Juvenescence’s Latest Venture, MDI Therapeutics, Inc., Targeting Fibrotic Disease
A biopharmaceutical company focused on treating aging and age-related disease
Juvenescence Confirms Close of Souvien Therapeutics and Announces High-level Appointments
Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.
Juvenescence Capitalizes BYOMass
Juvenescence is pleased to announce its latest equity investment in BYOMass Inc.
Juvenescence, The Buck Institute, and Insilico Medicine establish Napa Therapeutics
The Buck Institute is one of the leading research centers in the world focused solely on research on aging and the elimination of age-related disease.